General Medicine

GZGI Trial: Orforglipron in Obesity

GZGI TRIAL Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Phase 2, randomized, double-blind, placebo-controlled trial Objective:To assess the efficacy and safety of orforglipron, an oral non-peptide GLP-1 receptor agonist, for weight reduction in adults with obesity, or … Read More

Bridge-TIMI 73a Trial: Olezarsen for Hypertriglyceridemia

Bridge–TIMI 73a Trial Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk A randomized, placebo-controlled, double-blind trial Objective:To assess the efficacy and safety of olezarsen for lowering triglyceride levels in patients with moderate hypertriglyceridemia plus elevated cardiovascular risk and in … Read More

FCS BALANCE: Olezarsen in Familial Chylomicronemia Syndrome

FCS BALANCE Trial Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (FCS) A phase 3, double-blind, placebo-controlled trial Objective:To assess the efficacy and safety of olezarsen (given once every 4 weeks) in reducing fasting triglyceride level in patients with familial chylomicronemia … Read More

E-Cigarettes in Smoking Cessation: A New Tool in the Fight Against Tobacco

Introduction E-cigarettes, also known as electronic cigarettes or vapes, have emerged as a controversial but increasingly popular tool for smoking cessation. As healthcare providers, it’s crucial to understand the potential benefits and risks associated with e-cigarette use, especially in the … Read More

Target-HTN trial: Lorundrostat in Hypertension

The TARGET-HTN trial, published in JAMA in September 2023, investigated the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in treating patients with uncontrolled hypertension. This randomized, placebo-controlled, dose-ranging trial included 200 patients who were adults with uncontrolled hypertension … Read More

RADIANCE-HTN TRIO Trial: Renal Denervation in HTN

The RADIANCE-HTN TRIO trial, detailed in The Lancet in 2021, is another pivotal study in the domain of hypertension treatment, focusing on a challenging group of patients: those resistant to a standard triple combination pill. This trial delves into the … Read More

RADIANCE-HTN SOLO Trial: Renal Denervation in HTN

The RADIANCE-HTN SOLO trial, published in The Lancet in May 2018, marks a significant stride in hypertension treatment research. This trial focused on the safety and efficacy of a novel endovascular ultrasound renal denervation procedure compared to a sham procedure … Read More

Vitamin D to Prevent Cancer and CVD: VITAL Trial

VITAL Trial Vitamin D Summary The VITAL trial aimed to investigate whether supplementation with vitamin D reduces the risk of cancer or cardiovascular disease. It was a nationwide, randomized, placebo-controlled trial conducted with a two-by-two factorial design, including vitamin D3 … Read More

TIME Trial Summary: Morning vs. Evening dose of Antihypertensives

2022 TIME TRIAL Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK prospective, open-label, blinded-endpoint, randomized controlled trial IM Objective: To compare the major cardiovascular outcomes of evening dosing of antihypertensive medication … Read More

SUPPORT Trial Summary: Olmesartan in CHF

2015 SUPPORT TRIAL M Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure (CHF) prospective, open-label, randomized controlled trial Objective: to examine whether an additive treatment with an ARB, olmesartan, reduces the mortality and morbidity … Read More